{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:41:33Z","timestamp":1760532093722,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejps.2022.106186","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T21:16:19Z","timestamp":1649798179000},"page":"106186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Do we really target the receptors? Deposition and co-deposition of ICS-LABA fixed combination drugs"],"prefix":"10.1016","volume":"174","author":[{"given":"\u00c1rp\u00e1d","family":"Farkas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alp\u00e1r","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7889-636X","authenticated-orcid":false,"given":"G\u00e1bor","family":"Tomisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e1ta Marietta","family":"B\u00f6cskei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Kis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8552-1336","authenticated-orcid":false,"given":"J\u00e1nos","family":"Varga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2022.106186_bib0024","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/faat.1995.1144","article-title":"A multiple-path model of particle deposition in the rat lung","volume":"28","author":"Anjilvel","year":"1995","journal-title":"Fundamental Appl. Toxicol."},{"key":"10.1016\/j.ejps.2022.106186_bib0013","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jpba.2005.11.015","article-title":"High performance liquid chromatography assay method for simultaneous quantitation of formoterol and budesonide in Symbicort Turbuhaler","volume":"41","author":"Assi","year":"2006","journal-title":"J. Pharma. Biomed. Anal."},{"key":"10.1016\/j.ejps.2022.106186_bib0014","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijpharm.2017.02.057","article-title":"Real life emission characterization using COPD patient inhalation profiles when they inhaled using a fixed dose combination (FDC) of the medium strength Symbicort\u00ae Turbuhaler\u00ae","volume":"522","author":"Bagherisadegi","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2022.106186_bib0019","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1513\/pats.200409-045MS","article-title":"Distribution of receptor targets in the lungs","volume":"1","author":"Barnes","year":"2004","journal-title":"Proceedings of the Am. Thoracic Society"},{"key":"10.1016\/j.ejps.2022.106186_bib0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/jamp.2015.1220","article-title":"Effect of flow rate on in vitro aerodynamic performance of NEXThaler\u00ae in comparison with Diskus\u00ae and Turbohaler\u00ae dry powder inhalers","volume":"29","author":"Buttini","year":"2016","journal-title":"J. Aerosol Med. Pulmonary Drug Delivery"},{"key":"10.1016\/j.ejps.2022.106186_bib0023","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12931-018-0770-7","article-title":"Bechlomethasone diproprionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways","volume":"19","author":"Calzetta","year":"2018","journal-title":"Respiratory Res."},{"key":"10.1016\/j.ejps.2022.106186_bib0009","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijpharm.2015.05.076","article-title":"Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: A in-vitro comparison of Spiromax with Turbuhaler","volume":"491","author":"Chrystyn","year":"2015","journal-title":"Int. J. Pharma."},{"key":"10.1016\/j.ejps.2022.106186_bib0008","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1517\/17425247.2014.928282","article-title":"NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclamethasone and formoterol to treat large and small airways in asthma","volume":"11","author":"Corradi","year":"2014","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.ejps.2022.106186_bib0011","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejpb.2015.07.016","article-title":"Can \u2018extrafine\u2019 dry powder aerosols improve lung deposition?","volume":"96","author":"de Boer","year":"2015","journal-title":"Eur. J. Pharma. Biopharma."},{"key":"10.1016\/j.ejps.2022.106186_bib0016","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejps.2016.08.036","article-title":"Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort Turbuhaler dry powder fixed combination aerosol drug","volume":"93","author":"Farkas","year":"2016","journal-title":"Eur. J. Pharma. Sci."},{"key":"10.1016\/j.ejps.2022.106186_bib0017","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.rmed.2019.06.021","article-title":"Establishment of relationships between native and inhalation device specific spirometric parameters as a step towards patient tailored inhalation device selection","volume":"154","author":"Farkas","year":"2019","journal-title":"Respiratory Med."},{"key":"10.1016\/j.ejps.2022.106186_bib0022","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/sj.bjp.0707627","article-title":"A Holy Grail of asthma management: toward understanding how long-acting b2-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids","volume":"153","author":"Giembycz","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2022.106186_bib0001","unstructured":"GINA, 2021. (Global Initiative for Asthma) Global strategy for asthma management and prevention. http:\/\/ginasthma.org\/gina-reports\/."},{"key":"10.1016\/j.ejps.2022.106186_bib0002","unstructured":"GOLD, 2021. (Global Initiative for Chronic Obstructive Lung Disease) Global strategy for prevention, diagnosis and management of COPD. http:\/\/goldcopd.org\/2021-gold-reports\/."},{"key":"10.1016\/j.ejps.2022.106186_bib27","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1089\/jamp.2015.1223","article-title":"The ELLIPTA Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers","volume":"28","author":"Grant","year":"2015","journal-title":"J. of Aero. Med. and Pulm. Drug Del."},{"key":"10.1016\/j.ejps.2022.106186_bib0012","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s41030-016-0025-z","article-title":"Budesonide\/formoterol easyhaler: performance under simulated real-life conditions","volume":"3","author":"Haikarainen","year":"2017","journal-title":"Pulm. Therapy"},{"key":"10.1016\/j.ejps.2022.106186_bib26","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1089\/jamp.2015.1225","article-title":"In Vitro Dosing Performance of the ELLIPTA Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLungTM)","volume":"28","author":"Hamilton","year":"2015","journal-title":"J. of Aero. Med. and Pulm. Drug Del."},{"key":"10.1016\/j.ejps.2022.106186_bib0021","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.rmed.2010.04.012","article-title":"Choosing inhaler devices for asthma: Current knowledge and outstanding research needs","volume":"104","author":"Haughney","year":"2010","journal-title":"Respiratory Med."},{"key":"10.1016\/j.ejps.2022.106186_bib0020","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/j.1476-5381.2012.01881.x","article-title":"Regional quantification of muscarinic acetylcholine receptors and \u03b2-adrenoceptors in human airways","volume":"166","author":"Ikeda","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2022.106186_bib0007","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s13556-013-0003-9","article-title":"Fine particle profile of fluticasone propionate\/formoterol fumarate versus other combination products: the DIFFUSE study","volume":"3","author":"Johal","year":"2013","journal-title":"Combination Products in Therapy"},{"key":"10.1016\/j.ejps.2022.106186_bib0005","first-page":"4635","article-title":"Inspiratory flow resistance of dry powder inhalers (DPI)","volume":"44","author":"Kr\u00fcger","year":"2014","journal-title":"Eur. Res. J."},{"key":"10.1016\/j.ejps.2022.106186_bib0018","doi-asserted-by":"crossref","first-page":"22430","DOI":"10.1038\/s41598-020-79985-6","article-title":"Deposition distribution of the new coronavirus (SARS-CoV-2) in the human airway upon exposure to cough-generated droplets and aerosol particles","volume":"10","author":"Madas","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.ejps.2022.106186_bib0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jaerosci.2016.01.018","article-title":"Improvements and additions to the multiple path particle dosimetry model","volume":"99","author":"Miller","year":"2016","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.ejps.2022.106186_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12247-018-9352-y","article-title":"Effect of Human Error, Inhalation Flow, and Inhalation Volume on Dose Delivery from Ellipta\u00ae Dry-Powder Inhaler","volume":"14","author":"Saeed","year":"2018","journal-title":"Journal of Pharmeceutical Innovation"},{"key":"10.1016\/j.ejps.2022.106186_bib0006","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/089426804322994433","article-title":"In-vitro intra- and inter-inhaler flow rate dependentdosage emission from combination of budesonide and eformoterol in a dry powder inhaler","volume":"17","author":"Tarsin","year":"2004","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.ejps.2022.106186_bib0015","article-title":"Targeting the small airways with inhaled corticosteroid\/long-acting beta agonist dry powder inhalers: a functional respiratory Imaging study","volume":"34","author":"Watz","year":"2021","journal-title":"J. Aero. Med. Pulm. Drug Del."},{"key":"10.1016\/j.ejps.2022.106186_bib0003","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2147\/COPD.S234823","article-title":"Impact of single combination inhaler versus multiple inhalers to deliver the same medications for patients with asthma or COPD: a systematic literature review","volume":"15","author":"Zhang","year":"2020","journal-title":"Int. J. Chronic Obstructive Pulmonary Dis."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098722000719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098722000719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:02:07Z","timestamp":1760529727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098722000719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":27,"alternative-id":["S0928098722000719"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2022.106186","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do we really target the receptors? Deposition and co-deposition of ICS-LABA fixed combination drugs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2022.106186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106186"}}